Safety of Argatroban Infusion in Conduction Disturbances
brief summary
To determine change of QTc interval during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI)
detailed description
Primary objective:
To determine change of corrected QT interval (QTc) during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI).
Secondary objectives:
* Determination of the QTc interval after sufficient wash-out period by ECG-3 which needed to be performed \> 8 but ≤ 28 hours after termination of prolonged argatroban infusion. * Investigation of dependence of QTc interval on gender and applied doses. * Determination of coagulation status during argatroban therapy. * Assessment of safety-related events within the scope of anticoagulation with argatroban, for example bleeding events or thromboembolic events.
official title
SAICoDis - Safety of Argatroban Infusion in Conduction Disturbances. A Prospective, Open, Multicenter Safety Study to Investigate Conduction Disturbances in Patients Receiving Argatroban Therapy.